Apalutamide treatment and metastasis-free survival in prostate cancer

New England Journal of Medicine

Volumn 378, Issue 15, 2018, Pages 1408-1418

  Smith, Matthew R ^a   Saad, Fred ^b   Chowdhury, Simon ^c   Oudard, Stéphane ^d   Hadaschik, Boris A ^e   Graff, Julie N ^f,g   Olmos, David ^h,i   Mainwaring, Paul N ^j   Lee, Ji Youl ^k   Uemura, Hiroji ^l   Lopez Gitlitz, Angela ^m   Trudel, Géralyn C ^m   Espina, Byron M ⁿ   Shu, Youyi ⁿ   Park, Youn C ⁿ   Rackoff, Wayne R ⁿ   Yu, Margaret K ⁿ   Small, Eric J ⁿ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f VETERANS AFFAIRS PORTLAND HEALTH CARE SYSTEM   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h Structural Biology and Biocomputing Programme   (Spain)

ⁱ Hospitales Universitarios Regional y Virgen de la Victoria IBIMA   (Spain)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k The Catholic University of Korea   (South Korea)

^l YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^m JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APALUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TECHNETIUM 99M; ANTIANDROGEN; THIOHYDANTOIN DERIVATIVE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISTANT METASTASIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; FRACTURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METASTASIS FREE SURVIVAL; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEIZURE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; ADENOCARCINOMA; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; SECONDARY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EXANTHEMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; THIOHYDANTOINS;

EID: 85045420475     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1715546     Document Type: Article

References (13)

1. Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One 2015; 10(10): e0139440.
2. Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol 2014; 11:335-45.
3. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010; 17:R305-R315.
4. Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med 2017; 7(9): a030452.
5. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918-25.
6. Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013; 31: 3800-6.
7. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72:1494-503.
8. Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol 2016; 70:963-70.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
10. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59.
11. Beheshti M, Rezaee A, Geinitz H, Loidl W, Pirich C, Langsteger W. Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-fluorocholine PET/CT. J Nucl Med 2016; 57: Suppl 3: 55S-60S.
12. Eiber M, Fendler WP, Rowe SP, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 2017; 58:Suppl 2:67S-76S.
13. Schwarzenboeck SM, Rauscher I, Bluemel C, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med 2017; 58:1545-52.